Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Next Previous
Trial Profile

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Rivoceranib (Primary) ; Carboplatin; Pemetrexed
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

  • 04 Jul 2025 Status changed from not yet recruiting to discontinued. Reason the study was stopped: The sponsor's R&D strategy is adjusted.
  • 17 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Feb 2019.
  • 24 Dec 2018 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top